RekrutujeFaza III
Badanie fazy III leku atezolizumab i etoposide
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Badane leki: atezolizumabetoposide
+6
+6Rak płuca: badania kliniczne, Białystok
Badania kliniczne w obszarze: rak płuca, prowadzone w ośrodkach w mieście Białystok. Zobacz też wszystkie badania: rak płuca w Polsce.
21 badań: 21 rekrutuje.
Lista badań
RekrutujeObserwacyjne
Badanie obserwacyjne
Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment
RekrutujeFaza I/II
Badanie fazy I/II leku YL201 i atezolizumab
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Badane leki: YL201atezolizumab
+4
+4RekrutujeFaza II
Badanie fazy II leku EIK1001 i pembrolizumab
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Badane leki: EIK1001pembrolizumab
+17
+17RekrutujeFaza III
Badanie fazy III leku ZL-1310 i topotecan hydrochloride
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Badane leki: ZL-1310topotecan hydrochloride
+9
+9RekrutujeFaza II
Badanie fazy II leku pemetrexed disodium i pembrolizumab
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Badane leki: pemetrexed disodiumpembrolizumabvisugromabcarboplatin
RekrutujeFaza I
Rak nerki: badanie kliniczne fazy I
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
RekrutujeFaza I/II
Badanie fazy I/II leku budigalimab i pemetrexed
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With…
Badane leki: budigalimabpemetrexedcisplatintelisotuzumab adizutecan
+9
+9RekrutujeFaza III
Badanie fazy III leku tislelizumab i docetaxel
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic…
Badane leki: tislelizumabdocetaxelN-803
+8
+8RekrutujeFaza III
Badanie fazy III leku atezolizumab i BNT327
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Badane leki: atezolizumabBNT327carboplatincisplatin
+6
+6RekrutujeFaza II/III
Badanie fazy II/III leku paclitaxel i BNT327
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Badane leki: paclitaxelBNT327pembrolizumabpemetrexed disodium+14
+14RekrutujeFaza III
Badanie fazy III leku paclitaxel albumin-bound i paclitaxel
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Badane leki: paclitaxel albumin-boundpaclitaxelinfliximabpembrolizumab+19
+19RekrutujeFaza III
Badanie fazy III leku pemetrexed i carboplatin
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Badane leki: pemetrexedcarboplatinAZD2936mycophenolate mofetil+17
+17RekrutujeFaza III
Badanie fazy III leku cisplatin i paclitaxel
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Badane leki: cisplatinpaclitaxelgemcitabine hydrochloridecarboplatin
+23
+23RekrutujeFaza III
Badanie fazy III leku pembrolizumab i carboplatin
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC)…
Badane leki: pembrolizumabcarboplatinBAY 2927088cisplatin+28
+28RekrutujeFaza III
Badanie fazy III leku sacituzumab tirumotecan i carboplatin
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Badane leki: sacituzumab tirumotecancarboplatinpaclitaxel albumin-bounddexamethasone acetate+18
+18RekrutujeFaza III
Badanie fazy III leku gemcitabine hydrochloride i carboplatin
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC)…
Badane leki: gemcitabine hydrochloridecarboplatinpembrolizumabpemetrexed disodium+23
+23RekrutujeFaza III
Badanie fazy III leku toripalimab i tifcemalimab
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Badane leki: toripalimabtifcemalimab+7
+7RekrutujeFaza III
Badanie fazy III leku pembrolizumab i sotorasib
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced…
Badane leki: pembrolizumabsotorasibpemetrexeddexamethasone+31
+31RekrutujeFaza II
Badanie fazy II leku durvalumab i carboplatin
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Badane leki: durvalumabcarboplatincisplatinpaclitaxel
RekrutujeFaza III
Rak pęcherza moczowego: badanie fazy III leku durvalumab i infliximab
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Badane leki: durvalumabinfliximabmycophenolate mofetil+24
+24Rak płuca: inne miasta
Nie wiesz, które badanie jest dla Ciebie?
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.